Neuroblastoma overview: Difference between revisions

Jump to navigation Jump to search
Line 51: Line 51:


===Echocardiography or Ultrasound===
===Echocardiography or Ultrasound===
On ultrasound, neuroblastoma is characterized by a heterogeneous , vascular, and necrotic mass with localized areas of calcification.<ref name="radio">Neuroblastoma. Radiopaedia (2015) http://radiopaedia.org/articles/neuroblastoma Accessed on October, 8 2015</ref>
On ultrasound, neuroblastoma is characterized by a heterogeneous [[echogenicity]] due to the [[vascular]], [[necrotic]], and calcified content of the mass.<ref name="radio">Neuroblastoma. Radiopaedia (2015) http://radiopaedia.org/articles/neuroblastoma Accessed on October, 8 2015</ref>


===Other Imaging Findings===
===Other Imaging Findings===

Revision as of 22:41, 11 October 2015

Neuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neuroblastoma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neuroblastoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neuroblastoma overview

CDC on Neuroblastoma overview

Neuroblastoma overview in the news

Blogs on Neuroblastoma overview

Directions to Hospitals Treating Neuroblastoma

Risk calculators and risk factors for Neuroblastoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Haytham Allaham, M.D. [2]

Overview

Neuroblastoma is a malignant tumor that arises from neural crest cells, which are normally involved in the development of the sympathetic nervous system and adrenal glands.[1][2][3][4] In 1910, the term neuroblastoma was first used to describe the tumor by Dr. James Homer Wright, an American patholgist at Massachusetts General Hospital. Based on the degree of the cellular maturity and composition, neuroblastoma may be further classified into three subtypes according to the International Neuroblastoma Pathology Classification which include undifferentiated neruoblastoma, poorly differentiated neuroblastoma, and differentiating neuroblastoma.[5][6] Genes involved in the pathogenesis of neuroblastoma include NBPF10 gene, KIF1B gene, and ALK gene. Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy. The staging of neuroblastoma is based on the International Neuroblastoma Staging System (INSS).[7][8] Symptoms of neuroblastoma include fever, abdominal distension, constipation, cough, and weakness. A positive finding of a palpable abdominal mass, fever, and purple skin patches is suggestive of neuroblastoma. On labrotary studies an elevated levels of blood and urinary catecholamines, vanillylmandelic acid (VMA), and homovanillic acid (HVA) are suggestive of neuroblastoma. CT scan is the investigation of choice for the diagnosis of neuroblastoma.[8] On CT scan, neuroblastoma is characterized by a heterogeneous, calcified, and necrotic mass, that may encase surrounding vessels or invade surrounding tissues. The definitive diagnosis of nueroblastoma is confirmed by a biopsy. Children Oncology Group (COG) risk stratification system determines the protocol of management used for neuroblastoma patients. Low risk neuroblastoma patients are usually managed with either observation or surgical resection of the tumor. Intermidiate risk neuroblastoma patients are usually managed with neoadjuvant chemotherapy in advance of a definitive surgical resection. Whereas high risk neuroblastoma patients are usually managed with a combination of surgery, chemotherapy, radiation therapy, hematopoietic stem cell transplantation, differentiation therapy, and immunotherapy. Surgical intervention alone may be curative as a single therapeutic modality for the management of low risk neuroblastoma patients.[1][2][3][4]

Historical Perspective

In 1910, the term neuroblastoma was first used to describe the tumor by Dr. James Homer Wright, an American patholgist at Massachusetts General Hospital.[1]

Classification

Neuroblastic tumors may be grouped according to International Neuroblastoma Pathology Classification (Shimada classification) into two groups which include a schwannian stroma rich group and a schwannian stroma poor group. Based on the degree of the cellular maturity and composition, neuroblastoma may be further classified into three subtypes according to the International Neuroblastoma Pathology Classification which include undifferentiated neruoblastoma, poorly differentiated neuroblastoma, and differentiating neuroblastoma.[2][5][6]

Pathophysiology

Neuroblastoma arises from neural crest cells, which are normally involved in the development of the sympathetic nervous system and adrenal glands. Neuroblastoma is frequently located along the sympathetic nervous system structures. Genes involved in the pathogenesis of neuroblastoma include NBPF10 gene, KIF1B gene, and ALK gene. Neuroblastoma is associated with a number of syndromes that include neurofibromatosis type 1, Beckwith-Wiedemann syndrome, and DiGeorge syndrome. On gross pathology, a well defined, bulky, and tan colored mass is a characteristic finding of neuroblastoma. On microscopic histopathological analysis the presence of round blue cells separated by thin fibrous septa are characteristic findings of neuroblastoma.[3][1][4]

Causes

There are no known direct causes for neuroblastoma.[1]

Differentiating Multiple Myeloma from other Diseases

Intra-abdominal neuroblastoma must be differentiated from other diseases that cause abdominal distention and constipation such as Wilms tumor and ganglioneuroma. Whereas intra-thoracic neuroblastoma must be differentiated from other diseases that cause shortness of breath and chronic cough such as intrathoracic lymphoma and extra lobar pulmonary sequestration.[3][1]

Epidemiology and Demographics

Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy.[1] The overall incidence rate of neuroblastoma is approximately 4.9 per 1,000,000 individuals in the United States. The incidence of neuroblastoma decreases with age; the highest incidence is in the first year of life. Males are slightly more commonly affected with neuroblastoma than females. The male to female ratio is approximately 1.12 to 1. Neuroblastoma usually affects individuals of the Caucasian race. African American, Native Indian and Asian individuals are less likely to develop neuroblastoma.[9]

Risk Factors

There are no established risk factors for neuroblastoma.[1]

Screening

According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for neuroblastoma.[10]

Natural History, Complications and Prognosis

If left untreated, patients with neuroblastoma may progress to develop fatigue, loss of appetite, joint pain, and fever. Complications of neuroblastoma may include treatment-resistant diarrhea, Horner's syndrome, and transverse myelopathy. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis of neuroblastoma is generally regarded as poor.[3][1][4][2]

Diagnosis

Staging

According to the conventional International Neuroblastoma Staging System (INSS), there are 6 stages of neuroblastoma based on the tumor size, lymph node involvement, and presence of metastesis. However, according to a newly proposed International Neuroblastoma Risk Group Staging System (INRGSS), there are four stages of neuroblastoma based on the extent of dissemination and image findings. Neuroblastoma patients are risk stratified according to the Children Oncology Group (COG) risk stratification system into a low risk group, an intermediate risk group, and a high risk group based on the tumor INSS stage, the patient's age, tumor grade, and the amplification of MYCN gene.[1][7][8][4]

History and Symptoms

Symptoms of neuroblastoma include fever, abdominal distension, constipation, cough, and weakness.[1][11][8]

Physical Examination

A positive finding of a palpable abdominal mass, fever, and purple skin patches is suggestive of neuroblastoma.[1][11][4][8]

Laboratory Findings

An elevated levels of blood and urinary catecholamines, vanillylmandelic acid (VMA), and homovanillic acid (HVA) are suggestive of neuroblastoma.[4][1][8]

X Ray

On plain radiography neuroblastoma is characterized by an intraabdominal or intrathoracic soft tissue mass. Other findings of neuroblastoma on plain radiography include calcification and remodelling of surrounding bony structures.[3]

CT

CT scan is the investigation of choice for the diagnosis of neuroblastoma.[8] On CT scan, neuroblastoma is characterized by a heterogeneous, calcified, and necrotic mass, that may encase surrounding vessels or invade the surrounding tissues.[3]

MRI

On a T1 weighted brain MRI image, neurblastoma is characterized by a hyperintense, heterogeneous, and necrotic mass.[3]

Echocardiography or Ultrasound

On ultrasound, neuroblastoma is characterized by a heterogeneous echogenicity due to the vascular, necrotic, and calcified content of the mass.[3]

Other Imaging Findings

Other imaging studies for neuroblastoma include nuclear medicine studies such as fludeoxyglucose-18F positron emission tomography scan (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[12]

Other Diagnostic Studies

The definitive diagnosis of nueroblastoma is confirmed by a biopsy. Charecterstic findings for neuroblastoma on microscopic histopathological analysis can be found here.[2]

Treatment

Medical Therapy

Children Oncology Group (COG) risk stratification system determines the protocol of management used for neuroblastoma patients. Low risk neuroblastoma patients are usually managed with either observation or surgical resection of the tumor. Intermidiate risk neuroblastoma patients are usually managed with neoadjuvant chemotherapy in advance of a definitive surgical resection. Whereas high risk neuroblastoma patients are usually managed with a combination of surgery, chemotherapy, radiation therapy, hematopoietic stem cell transplantation, differentiation therapy, and immunotherapy.[4]

Surgery

Surgical intervention alone may be curative as a single therapeutic modality for the management of low risk neuroblastoma patients.[4]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 Neuroblastoma. Wikipedia(2015) https://en.wikipedia.org/wiki/Neuroblastoma Accessed on October, 4 2015
  2. 2.0 2.1 2.2 2.3 2.4 Neuroblastoma. Libre Pathology(2015) http://librepathology.org/wiki/index.php/Adrenal_gland#Neuroblastoma Accessed on October, 5 2015
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Neuroblastoma. Radiopaedia(2015) http://radiopaedia.org/articles/neuroblastoma Accessed on October, 5 2015
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Neuroblastoma Treatment for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#link/_534_toc Accessed on October, 7 2015
  5. 5.0 5.1 Neuroblastoma, Ganglioneuroblastoma and Ganglioneuroma. Stanford Medicine Surgical Pathology Criteria(2015) http://surgpathcriteria.stanford.edu/srbc/neuroblastoma-ganglioneuroblastoma-ganglioneuroma/ Accessed on October, 5 2015
  6. 6.0 6.1 Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S; et al. (2001). "International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group". Cancer. 92 (9): 2451–61. PMID 11745303.
  7. 7.0 7.1 Davidoff AM (2012). "Neuroblastoma". Semin Pediatr Surg. 21 (1): 2–14. doi:10.1053/j.sempedsurg.2011.10.009. PMC 3261589. PMID 22248965.
  8. 8.0 8.1 8.2 8.3 8.4 8.5 8.6 Colon NC, Chung DH (2011). "Neuroblastoma". Adv Pediatr. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMC 3668791. PMID 21736987.
  9. Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF (2011). "Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006". Pediatr Blood Cancer. 56 (1): 50–7. doi:10.1002/pbc.22559. PMC 4251713. PMID 21108439.
  10. Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015
  11. 11.0 11.1 Neuroblastoma Childhood: Symptoms and Signs. Cancer.net http://www.cancer.net/cancer-types/neuroblastoma-childhood/symptoms-and-signs Accessed on October, 7 2015
  12. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). "123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma". J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.


Template:WikiDoc Sources